written on 27.05.2014

Allergan investors want up to $200 per share from Valeant


Valeant Pharmaceuticals has already promised it will raise its $47 billion offer for Allergan Wednesday during a webcast for investors. But according to a JPMorgan survey, that new offer had better be at least $180 per share if the Canadian deal machine wants to make some headway.